Kinase Domain Is a Dynamic Hub for Driving LRRK2 Allostery

Autor: Susan S. Taylor, Pallavi Kaila-Sharma, Jui-Hung Weng, Phillip Aoto, Sven H. Schmidt, Stefan Knapp, Sebastian Mathea, Friedrich W. Herberg

Publikováno v: Frontiers in Molecular Neuroscience, Vol 13 (2020)

Protein kinases and GTPases are the two major molecular switches that regulate much of biology, and both of these domains are embedded within the large multi-domain Leucine-Rich Repeat Kinase 2 (LRRK2). Mutations in LRRK2 are the most common cause of

Externí odkaz: https://doaj.org/article/477485f49371480f8b856a22452f7660

mTOR independent alteration in ULK1 Ser758 phosphorylation following chronic LRRK2 kinase inhibition

Autor: Manzoni, Claudia, Mamais, Adamantios, Dihanich, Sybille, Soutar, Marc P.M., Plun-Favreau, Helene, Bandopadhyay, Rina, Abeti, Rosella, Giunti, Paola, Hardy, John, R. Cookson, Mark, Tooze, Sharon A., Lewis, Patrick A.

Publikováno v: Bioscience Reports

Unc-51 Like Kinase 1 (ULK1) is a critical regulator of the biogenesis of autophagosomes, the central component of the catabolic macroautophagy pathway. Regulation of ULK1 activity is dependent upon several phosphorylation events acting to repress or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::03a93a30d01542c2cccd6ceaae7ebf39
https://centaur.reading.ac.uk/76657/9/BSR20171669.full.pdf

Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries

Autor: Tomiyama, Hiroyuki

Publikováno v: Movement Disorders. 21(8):1102-1108

We screened LRRK2 mutations in exon 41 in 904 parkin-negative Parkinson’s disease (PD) patients (868 probands) from 18 countries across 5 continents. We found 3 heterozygous missense (novel I2012T, G2019S, and I2020T) mutations in LRRK2 exon 41. We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=jairo_______::6da87e6f4acb5d262139020b030d1f79
http://hdl.handle.net/10271/83

mTOR independent alteration in ULK1 Ser758 phosphorylation following chronic LRRK2 kinase inhibition.

Autor: Manzoni C; School of Pharmacy, University of Reading, Whiteknights, Reading RG6 6AP, U.K. c.manzoni@reading.ac.uk.; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, U.K., Mamais A; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, U.S.A., Dihanich S; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, U.K., Soutar MPM; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, U.K., Plun-Favreau H; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, U.K., Bandopadhyay R; Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, 1 Wakefield Street London WC1N 1PJ, U.K., Abeti R; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, U.K.; Department of Molecular Neuroscience, UCL Institute of Neurology, Ataxia Centre, Queen Square, London WC1N 3BG, United Kingdom., Giunti P; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, U.K.; Department of Molecular Neuroscience, UCL Institute of Neurology, Ataxia Centre, Queen Square, London WC1N 3BG, United Kingdom., Hardy J; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, U.K., R Cookson M; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, U.S.A., Tooze SA; The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, U.K., Lewis PA; School of Pharmacy, University of Reading, Whiteknights, Reading RG6 6AP, U.K.; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, U.K.

Publikováno v: Bioscience reports [Biosci Rep] 2018 Apr 20; Vol. 38 (2). Date of Electronic Publication: 2018 Apr 20 (Print Publication: 2018).